Beta Bionics Inc (BBNX)

$15.84 +1.73 (12.26%)
Market Cap 625.81M
Revenue (ttm) 100.25M
Net Income (ttm) -73.20M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -73.02%
Debt to Equity Ratio 0.00
Volume 644,488
Avg Vol 1,150,652
Day's Range N/A - N/A
Shares Out 44.99M
Stochastic %K 37%
Beta 3.13
Analysts Strong Sell
Price Target $19.99

Company Profile

Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin with...

Industry: Medical Devices
Sector: Healthcare
Phone: 949 427 7785
Address:
11 Hughes, Irvine, United States
UrMomsCrater
UrMomsCrater Aug. 5 at 5:46 PM
$BBNX trash
1 · Reply
deepthinker
deepthinker Jul. 31 at 9:04 PM
$MODD $BBNX is puking cash for relatively little gain. Stock slammed. They’re pitching a tubed pump for another year when no one wants the damn tube.
0 · Reply
deepthinker
deepthinker Jul. 30 at 6:27 PM
$BBNX They’re going to spend $250 million to pick up maybe $100 million of revenue over the next 3 years. Right now, their EV is about $400 million and the 2027 rev is $180 million, so the rev multiple is around 2.25x. Applying that to the incremental $100 million, that’s $225 million of added value. So, the next 3 years of spending don’t produce a return.
0 · Reply
deepthinker
deepthinker Jul. 30 at 4:11 PM
$BBNX Incredible margins. It’s so obvious that this should be merged with another player to reduce combined sales and marketing expense. The idea that $PODD just watches as competitors slaughter one another on spend is ridiculous. At the end of the day, Insulet will just vacuum up whatever pieces are left. Also, no other patch pumps, so Insulet just cruises to victory.
1 · Reply
EarningsInsider
EarningsInsider Jul. 29 at 9:47 PM
https://www.marketbeat.com/earnings/reports/2026-7-29-beta-bionics-inc-stock/ $BBNX Beta Bionics Earnings Transcript
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Jul. 29 at 8:11 PM
$BBNX Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.53 down -35.90% YoY • Reported revenue of $32.01M up 37.76% YoY • Beta Bionics, Inc. maintains its 2026 revenue guidance of $131 million to $136 million and PBP channel reimbursement guidance of 37% to 39%, while raising estimated gross margin to 58.5% to 59.5%.
0 · Reply
MODDBlueInMyBlood
MODDBlueInMyBlood Jul. 22 at 3:24 PM
$MODD its called power projection and aura farming. Watch. $PODD $MDT $TNDM $BBNX PODD IS A DECADE OLD TECH MEDTRONIC = FED TRONIC TANDEM = NO MONEY WHERES THE MONEY BETA BIONICS, BAD NAME MODD IS COMING IN HOT. LETS GO. BUY US WHILE YOU CAN OR WE WILL SMOKE YOU. TIME IS UP ME ✊️💎 YOU ✊️📃
2 · Reply
MODDBlueInMyBlood
MODDBlueInMyBlood Jul. 21 at 3:29 PM
$MODD my brother, not a single insulin pump stock is up right now Its a bear market for pumps $PODD $MDT $TNDM $BBNX $ROCHE Literally the only excpwtion is ypsomed, which does more than just pumps. Pop an oxy and vibrate for a minute. You are concerned over nothing. Hold 💎✊️
0 · Reply
deepthinker
deepthinker Jul. 17 at 1:11 PM
$TRIB Perceptive has left Gillard in place coming on three years now. Why? Because he’s (apparently) progressed the CGM to near the finish line, which is the main thing they care about. Perceptive is always looking for extra base hits, and CGM’s qualify. The model is $BBNX, which is one of several companies eating Insulet’s crumbs, but those are some pretty big crumbs. There are Dexcom/Abbott crumbs out there, as well.
0 · Reply
XI_JINPING_BOUGHT_BABA
XI_JINPING_BOUGHT_BABA Jul. 15 at 1:22 AM
$MODD I am long MODD, but it is not a guaranteed win. Beta Bionic’s $BBNX Mint pump is the pivot, but better, and targeted for commercial launch q2 2027, only 6-9 months after Pivot. If Pivot isn’t a commercial hit within the next 6 months, $MODD will lose, and it is a clear sell. Hold me honest to my word - this stock is down tremendously or up tremendously by EOY, with no inbetween.
2 · Reply
Latest News on BBNX
Beta Bionics price target raised to $15.50 from $13 at BofA

2026-07-30T13:42:04.000Z - 8 days ago

Beta Bionics price target raised to $15.50 from $13 at BofA

Beta Bionics price target lowered to $30.40 from $32 at Ladenburg

2026-07-30T13:35:44.000Z - 8 days ago

Beta Bionics price target lowered to $30.40 from $32 at Ladenburg

Beta Bionics Earnings Call Transcript: Q2 2026

Jul 29, 2026, 4:30 PM EDT - 8 days ago

Beta Bionics Earnings Call Transcript: Q2 2026

Beta Bionics Earnings release: Q2 2026

Jul 29, 2026, 4:30 PM EDT - 8 days ago

Beta Bionics Earnings release: Q2 2026

Beta Bionics Slides: Q2 2026

Jul 29, 2026, 4:30 PM EDT - 8 days ago

Beta Bionics Slides: Q2 2026

Beta Bionics Quarterly report: Q2 2026

Jul 29, 2026, 4:30 PM EDT - 8 days ago

Beta Bionics Quarterly report: Q2 2026

Beta Bionics reports Q2 EPS (53c), consensus (56c)

2026-07-29T20:16:50.000Z - 8 days ago

Beta Bionics reports Q2 EPS (53c), consensus (56c)

Beta Bionics backs FY26 revenue view $131M-$136M, consensus $133.48M

2026-07-29T20:15:51.000Z - 8 days ago

Beta Bionics backs FY26 revenue view $131M-$136M, consensus $133.48M

Beta Bionics Announces Second Quarter 2026 Financial Results and Updates Full Year 2026 Guidance

Jul 29, 2026, 4:02 PM EDT - 8 days ago

Beta Bionics Announces Second Quarter 2026 Financial Results and Updates Full Year 2026 Guidance

Beta Bionics resumed with a Buy at UBS

2026-07-28T11:55:23.000Z - 10 days ago

Beta Bionics resumed with a Buy at UBS

Beta Bionics price target raised to $19 from $17 at Goldman Sachs

2026-07-15T10:26:24.000Z - 23 days ago

Beta Bionics price target raised to $19 from $17 at Goldman Sachs

Beta Bionics price target raised to $22 from $18 at Truist

2026-07-13T13:50:36.000Z - 25 days ago

Beta Bionics price target raised to $22 from $18 at Truist

Beta Bionics to Announce Second Quarter 2026 Financial Results on July 29, 2026

Jul 1, 2026, 8:30 AM EDT - 5 weeks ago

Beta Bionics to Announce Second Quarter 2026 Financial Results on July 29, 2026

Johnson Fistel Continues Investigation of Beta Bionics, Inc. (BBNX)

Jun 15, 2026, 10:25 AM EDT - 7 weeks ago

Johnson Fistel Continues Investigation of Beta Bionics, Inc. (BBNX)

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth

Jun 12, 2026, 12:50 PM EDT - 2 months ago

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth

Robbins LLP Reminds BBNX Stockholders of its Investigation into Beta Bionics, Inc.; Contact the Firm for Information

Jun 5, 2026, 6:09 PM EDT - 2 months ago

Robbins LLP Reminds BBNX Stockholders of its Investigation into Beta Bionics, Inc.; Contact the Firm for Information

Beta Bionics, Inc. (BBNX) Investigation: Johnson Fistel Investigates Investor Losses Following Slower New Patient Start Growth

Jun 4, 2026, 10:18 AM EDT - 2 months ago

Beta Bionics, Inc. (BBNX) Investigation: Johnson Fistel Investigates Investor Losses Following Slower New Patient Start Growth

Beta Bionics management to meet with Piper Sandler

2026-06-03T20:55:26.000Z - 2 months ago

Beta Bionics management to meet with Piper Sandler

Beta Bionics, Inc. Securities Fraud Investigation – Robbins LLP is Investigating Investor Losses in BBNX Due to Possible Violations of Securities Laws

Jun 3, 2026, 4:09 PM EDT - 2 months ago

Beta Bionics, Inc. Securities Fraud Investigation – Robbins LLP is Investigating Investor Losses in BBNX Due to Possible Violations of Securities Laws

Beta Bionics Investors Suffer Significant Losses After Company Reports Slower New Patient Start Growth; Contact Johnson Fistel

Jun 3, 2026, 9:47 AM EDT - 2 months ago

Beta Bionics Investors Suffer Significant Losses After Company Reports Slower New Patient Start Growth; Contact Johnson Fistel

Beta Bionics Investors Who Suffered Losses May Be Eligible for Recovery-Learn More Today, Contact Johnson Fistel

Jun 2, 2026, 11:14 AM EDT - 2 months ago

Beta Bionics Investors Who Suffered Losses May Be Eligible for Recovery-Learn More Today, Contact Johnson Fistel

Beta Bionics First in Automated Insulin Delivery to Publish Near Real-Time Real-World Data on a Public Website

Jun 2, 2026, 9:00 AM EDT - 2 months ago

Beta Bionics First in Automated Insulin Delivery to Publish Near Real-Time Real-World Data on a Public Website

Robbins LLP is Investigating Allegations that the Officers and Directors of Beta Bionics, Inc. (BBNX) Violated Securities Laws and Breached Fiduciary Duties to Shareholders

Jun 1, 2026, 6:19 PM EDT - 2 months ago

Robbins LLP is Investigating Allegations that the Officers and Directors of Beta Bionics, Inc. (BBNX) Violated Securities Laws and Breached Fiduciary Duties to Shareholders

Beta Bionics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their Losses

Jun 1, 2026, 9:19 AM EDT - 2 months ago

Beta Bionics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their Losses

Beta Bionics price target lowered to $17 from $19 at Goldman Sachs

2026-05-27T10:23:13.000Z - 2 months ago

Beta Bionics price target lowered to $17 from $19 at Goldman Sachs

Beta Bionics price target raised to $13 from $11 at BofA

2026-05-22T11:58:04.000Z - 2 months ago

Beta Bionics price target raised to $13 from $11 at BofA

Beta Bionics Transcript: AGM 2026

May 21, 2026, 5:00 PM EDT - 2 months ago

Beta Bionics Transcript: AGM 2026

Beta Bionics Updates Commercialization Timeline Expectations for Mint™, its Patch Pump in Development

May 21, 2026, 4:04 PM EDT - 2 months ago

Beta Bionics Updates Commercialization Timeline Expectations for Mint™, its Patch Pump in Development

Beta Bionics price target lowered to $11 from $23 at BofA

2026-05-18T12:00:44.000Z - 2 months ago

Beta Bionics price target lowered to $11 from $23 at BofA

Beta Bionics Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 2:20 PM EDT - 3 months ago

Beta Bionics Transcript: Bank of America Global Healthcare Conference 2026

Beta Bionics to Present at the Bank of America Securities Health Care Conference

Apr 27, 2026, 4:25 PM EDT - 3 months ago

Beta Bionics to Present at the Bank of America Securities Health Care Conference

Beta Bionics price target lowered to $20 from $22 at Stifel

2026-04-22T11:50:58.000Z - 3 months ago

Beta Bionics price target lowered to $20 from $22 at Stifel

Beta Bionics price target lowered to $20 from $32 at Piper Sandler

2026-04-22T11:09:16.000Z - 3 months ago

Beta Bionics price target lowered to $20 from $32 at Piper Sandler

Beta Bionics reports Q1 EPS (49c), consensus (45c)

2026-04-21T20:31:34.000Z - 3 months ago

Beta Bionics reports Q1 EPS (49c), consensus (45c)

Beta Bionics Earnings Call Transcript: Q1 2026

Apr 21, 2026, 4:30 PM EDT - 3 months ago

Beta Bionics Earnings Call Transcript: Q1 2026

Beta Bionics Earnings release: Q1 2026

Apr 21, 2026, 4:30 PM EDT - 3 months ago

Beta Bionics Earnings release: Q1 2026

Beta Bionics Slides: Q1 2026

Apr 21, 2026, 4:30 PM EDT - 3 months ago

Beta Bionics Slides: Q1 2026

Beta Bionics Quarterly report: Q1 2026

Apr 21, 2026, 4:30 PM EDT - 3 months ago

Beta Bionics Quarterly report: Q1 2026

Beta Bionics sees FY26 revenue $131M-$136M, consensus $132.58M

2026-04-21T20:28:56.000Z - 3 months ago

Beta Bionics sees FY26 revenue $131M-$136M, consensus $132.58M

Beta Bionics Announces First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance

Apr 21, 2026, 4:03 PM EDT - 3 months ago

Beta Bionics Announces First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance

Beta Bionics price target lowered to $18 from $25 at Truist

2026-04-15T12:36:49.000Z - 4 months ago

Beta Bionics price target lowered to $18 from $25 at Truist

Beta Bionics, Inc. Investigated by the Portnoy Law Firm

Apr 14, 2026, 9:00 AM EDT - 4 months ago

Beta Bionics, Inc. Investigated by the Portnoy Law Firm

Beta Bionics Proxy statement: Proxy filing

Apr 10, 2026, 8:00 AM EDT - 4 months ago

Beta Bionics Proxy statement: Proxy filing

Beta Bionics Proxy statement: Proxy filing

Apr 10, 2026, 8:00 AM EDT - 4 months ago

Beta Bionics Proxy statement: Proxy filing

Beta Bionics to Announce First Quarter 2026 Financial Results on April 21, 2026

Mar 30, 2026, 4:11 PM EDT - 4 months ago

Beta Bionics to Announce First Quarter 2026 Financial Results on April 21, 2026

Beta Bionics pullback an ‘overreaction,’ says Lake Street

2026-03-24T12:46:35.000Z - 4 months ago

Beta Bionics pullback an ‘overreaction,’ says Lake Street

Beta Bionics management to meet virtually with Lake Street

2026-03-13T15:00:31.000Z - 5 months ago

Beta Bionics management to meet virtually with Lake Street

Beta Bionics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 4, 2026, 10:30 AM EST - 5 months ago

Beta Bionics Transcript: TD Cowen 46th Annual Health Care Conference

Beta Bionics files automatic mixed securities shelf

2026-02-24T22:20:44.000Z - 5 months ago

Beta Bionics files automatic mixed securities shelf

Beta Bionics to Present at the TD Cowen 46th Annual Health Care Conference

Feb 19, 2026, 4:05 PM EST - 6 months ago

Beta Bionics to Present at the TD Cowen 46th Annual Health Care Conference

Beta Bionics Earnings Call Transcript: Q4 2025

Feb 17, 2026, 4:30 PM EST - 6 months ago

Beta Bionics Earnings Call Transcript: Q4 2025

Beta Bionics Annual report: Q4 2025

Feb 17, 2026, 4:30 PM EST - 6 months ago

Beta Bionics Annual report: Q4 2025

Beta Bionics Earnings release: Q4 2025

Feb 17, 2026, 4:30 PM EST - 6 months ago

Beta Bionics Earnings release: Q4 2025

Beta Bionics Slides: Q4 2025

Feb 17, 2026, 4:30 PM EST - 6 months ago

Beta Bionics Slides: Q4 2025

Beta Bionics Announces Fourth Quarter and Full Year 2025 Financial Results and Introduces Annual Guidance for Full Year 2026

Feb 17, 2026, 4:05 PM EST - 6 months ago

Beta Bionics Announces Fourth Quarter and Full Year 2025 Financial Results and Introduces Annual Guidance for Full Year 2026

Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation Into Beta Bionics, Inc. (NASDAQ: BBNX)

Jan 21, 2026, 6:15 PM EST - 7 months ago

Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation Into Beta Bionics, Inc. (NASDAQ: BBNX)

Beta Bionics to Announce Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

Jan 15, 2026, 4:03 PM EST - 7 months ago

Beta Bionics to Announce Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

Beta Bionics, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights - BBNX

Jan 15, 2026, 1:36 AM EST - 7 months ago

Beta Bionics, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights - BBNX

Beta Bionics Announces Preliminary, Unaudited Fourth Quarter 2025 Topline Financial Results and Key Metrics

Jan 8, 2026, 4:04 PM EST - 7 months ago

Beta Bionics Announces Preliminary, Unaudited Fourth Quarter 2025 Topline Financial Results and Key Metrics

UrMomsCrater
UrMomsCrater Aug. 5 at 5:46 PM
$BBNX trash
1 · Reply
deepthinker
deepthinker Jul. 31 at 9:04 PM
$MODD $BBNX is puking cash for relatively little gain. Stock slammed. They’re pitching a tubed pump for another year when no one wants the damn tube.
0 · Reply
deepthinker
deepthinker Jul. 30 at 6:27 PM
$BBNX They’re going to spend $250 million to pick up maybe $100 million of revenue over the next 3 years. Right now, their EV is about $400 million and the 2027 rev is $180 million, so the rev multiple is around 2.25x. Applying that to the incremental $100 million, that’s $225 million of added value. So, the next 3 years of spending don’t produce a return.
0 · Reply
deepthinker
deepthinker Jul. 30 at 4:11 PM
$BBNX Incredible margins. It’s so obvious that this should be merged with another player to reduce combined sales and marketing expense. The idea that $PODD just watches as competitors slaughter one another on spend is ridiculous. At the end of the day, Insulet will just vacuum up whatever pieces are left. Also, no other patch pumps, so Insulet just cruises to victory.
1 · Reply
EarningsInsider
EarningsInsider Jul. 29 at 9:47 PM
https://www.marketbeat.com/earnings/reports/2026-7-29-beta-bionics-inc-stock/ $BBNX Beta Bionics Earnings Transcript
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Jul. 29 at 8:11 PM
$BBNX Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.53 down -35.90% YoY • Reported revenue of $32.01M up 37.76% YoY • Beta Bionics, Inc. maintains its 2026 revenue guidance of $131 million to $136 million and PBP channel reimbursement guidance of 37% to 39%, while raising estimated gross margin to 58.5% to 59.5%.
0 · Reply
MODDBlueInMyBlood
MODDBlueInMyBlood Jul. 22 at 3:24 PM
$MODD its called power projection and aura farming. Watch. $PODD $MDT $TNDM $BBNX PODD IS A DECADE OLD TECH MEDTRONIC = FED TRONIC TANDEM = NO MONEY WHERES THE MONEY BETA BIONICS, BAD NAME MODD IS COMING IN HOT. LETS GO. BUY US WHILE YOU CAN OR WE WILL SMOKE YOU. TIME IS UP ME ✊️💎 YOU ✊️📃
2 · Reply
MODDBlueInMyBlood
MODDBlueInMyBlood Jul. 21 at 3:29 PM
$MODD my brother, not a single insulin pump stock is up right now Its a bear market for pumps $PODD $MDT $TNDM $BBNX $ROCHE Literally the only excpwtion is ypsomed, which does more than just pumps. Pop an oxy and vibrate for a minute. You are concerned over nothing. Hold 💎✊️
0 · Reply
deepthinker
deepthinker Jul. 17 at 1:11 PM
$TRIB Perceptive has left Gillard in place coming on three years now. Why? Because he’s (apparently) progressed the CGM to near the finish line, which is the main thing they care about. Perceptive is always looking for extra base hits, and CGM’s qualify. The model is $BBNX, which is one of several companies eating Insulet’s crumbs, but those are some pretty big crumbs. There are Dexcom/Abbott crumbs out there, as well.
0 · Reply
XI_JINPING_BOUGHT_BABA
XI_JINPING_BOUGHT_BABA Jul. 15 at 1:22 AM
$MODD I am long MODD, but it is not a guaranteed win. Beta Bionic’s $BBNX Mint pump is the pivot, but better, and targeted for commercial launch q2 2027, only 6-9 months after Pivot. If Pivot isn’t a commercial hit within the next 6 months, $MODD will lose, and it is a clear sell. Hold me honest to my word - this stock is down tremendously or up tremendously by EOY, with no inbetween.
2 · Reply
JFDI
JFDI Jun. 28 at 11:26 PM
$BBNX mid range but on lsit
0 · Reply
ap20
ap20 Jun. 25 at 3:57 PM
$BBNX Congrats longs. No position, unfortunately.
0 · Reply
LinzonTard
LinzonTard Jun. 20 at 10:12 PM
$PODD I’m thinking about investing in the pump/CGM space and the field is getting crowded. I think $BBNX wins with simplicity for patients and doctors. It learns dosing itself and meals are not carbohydrate counting, but easy Bolus dosing based on historical learned meals: less, same, more than usual. This will win market share.
1 · Reply
topstockalerts
topstockalerts Jun. 4 at 10:13 PM
$BBNX the market seems reluctant to let this fade.
0 · Reply
diastud
diastud Jun. 2 at 1:14 AM
$BBNX volume is slowly increasing. This will be 2-3x soon
2 · Reply
ThePatch
ThePatch May. 28 at 7:50 PM
$BBNX has anyone dug into this compares to the Twiist pump?
0 · Reply
1trendingup
1trendingup May. 22 at 2:13 AM
$BBNX https://www.globenewswire.com/news-release/2026/05/21/3299712/0/en/beta-bionics-updates-commercialization-timeline-expectations-for-mint-its-patch-pump-in-development.html No wonder what this is up the last few days…
0 · Reply
deepthinker
deepthinker May. 18 at 3:32 PM
$MODD $BBNX has a patch pump coming in late 2027. I wonder if they could slap the iLet AID on Pivot, and how long that would take to get through the FDA?
1 · Reply
NVDAMillionaire
NVDAMillionaire May. 14 at 2:33 PM
$BBNX Really good write-up that perfectly summarizes BBNX's present situation. So if you want to bring your BBNX knowledge up to date or just discover BBNX, this is required reading. https://everyticker.com/quote/BBNX/analysis/pharmacy-channel-inflection-how-beta-bionics-is-building-a-saas-like-diabetes-franchise-nasdaq-bbnx
0 · Reply
deepthinker
deepthinker May. 13 at 2:18 PM
$BBNX So, they had about $200 million end of Q1. That’s about 8 quarters at current burn. So, they’ll be out of money Q1 of 2028 unless they dilute. The growth is still good, considering they have no patch pump, but I’m not clear what’s going to happen when they burn through their stash.
2 · Reply
MarketBeat
MarketBeat May. 13 at 6:06 AM
https://marketbeat.com/a/8651341/ $BBNX Beta Bionics Touts Pharmacy Push, iLet Momentum and 2027 Mint Patch Pump Plans
0 · Reply
deepthinker
deepthinker May. 10 at 3:18 PM
$BBNX I would be surprised if we don’t get a bid given the crushed stock price here. Easy to consolidate and clean up the SG&A. Toss the iLet in another bag. Too many players in this space.
0 · Reply